GPR82

Summary

GPR82 (G protein-coupled receptor 82, HGNC:4533) is a protein-coding gene on chromosome Xp11.4, encoding Probable G-protein coupled receptor 82 (Q96P67). Orphan receptor.

The protein encoded by this gene is an orphan G protein-coupled receptor of unknown function. The encoded protein is a member of a family of proteins that contain seven transmembrane domains and transduce extracellular signals through heterotrimeric G proteins.

Source: NCBI Gene 27197 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 4 total — 2 pathogenic
• Druggable target: yes
• MANE Select transcript: NM_080817

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4533
Approved symbol	GPR82
Name	G protein-coupled receptor 82
Location	Xp11.4
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000171657
Ensembl biotype	protein_coding
OMIM	300748
Entrez	27197

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 2 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000302548, ENST00000497180, ENST00000898141

RefSeq mRNA: 1 — MANE Select: NM_080817 NM_080817

CCDS: CCDS14259

Canonical transcript exons

ENST00000302548 — 3 exons

Exon	Start	End
ENSE00001171944	41726993	41730130
ENSE00001221768	41726773	41726843
ENSE00001221776	41724181	41724289

Expression profiles

Bgee: expression breadth ubiquitous, 144 present calls, max score 71.87.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1947 / max 10.9782, expressed in 96 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
196046	0.1947	96

Top tissues by expression

244 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
epithelium of nasopharynx	UBERON:0001951	71.87	gold quality
buccal mucosa cell	CL:0002336	71.13	silver quality
palpebral conjunctiva	UBERON:0001812	70.63	gold quality
vermiform appendix	UBERON:0001154	68.65	gold quality
colonic epithelium	UBERON:0000397	67.07	silver quality
jejunal mucosa	UBERON:0000399	65.56	gold quality
lymph node	UBERON:0000029	65.55	gold quality
calcaneal tendon	UBERON:0003701	64.65	gold quality
tonsil	UBERON:0002372	63.82	gold quality
leukocyte	CL:0000738	63.72	gold quality
monocyte	CL:0000576	63.43	gold quality
caecum	UBERON:0001153	62.50	gold quality
rectum	UBERON:0001052	61.93	gold quality
amniotic fluid	UBERON:0000173	61.43	gold quality
ileal mucosa	UBERON:0000331	60.42	gold quality
duodenum	UBERON:0002114	59.77	gold quality
gall bladder	UBERON:0002110	58.86	gold quality
mucosa of transverse colon	UBERON:0004991	57.65	gold quality
bone marrow cell	CL:0002092	57.51	gold quality
granulocyte	CL:0000094	56.80	gold quality
smooth muscle tissue	UBERON:0001135	56.74	gold quality
adrenal tissue	UBERON:0018303	56.59	gold quality
tendon	UBERON:0000043	56.13	gold quality
small intestine	UBERON:0002108	55.88	gold quality
lower lobe of lung	UBERON:0008949	55.33	silver quality
blood	UBERON:0000178	54.93	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	54.83	gold quality
small intestine Peyer’s patch	UBERON:0003454	54.76	gold quality
cardiac muscle of right atrium	UBERON:0003379	54.34	gold quality
left ventricle myocardium	UBERON:0006566	54.23	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.06

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

113 targeting GPR82, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4713-3P	100.00	65.92	505
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-302A-3P	99.89	71.23	1777
HSA-MIR-302B-3P	99.89	71.23	1777

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Gpr82	ENSMUSG00000047678
rattus_norvegicus	Gpr82	ENSRNOG00000039762

Paralogs (15): GPR31 (ENSG00000120436), GPR42 (ENSG00000126251), FFAR2 (ENSG00000126262), FFAR1 (ENSG00000126266), OXER1 (ENSG00000162881), OXGR1 (ENSG00000165621), P2RY1 (ENSG00000169860), P2RY6 (ENSG00000171631), P2RY2 (ENSG00000175591), HCAR2 (ENSG00000182782), FFAR3 (ENSG00000185897), P2RY4 (ENSG00000186912), HCAR1 (ENSG00000196917), SUCNR1 (ENSG00000198829), HCAR3 (ENSG00000255398)

Protein

Protein identifiers

Probable G-protein coupled receptor 82 — Q96P67 (reviewed: Q96P67)

All UniProt accessions (1): Q96P67

UniProt curated annotations — full annotation on UniProt →

Function. Orphan receptor.

Subcellular location. Cell membrane.

Similarity. Belongs to the G-protein coupled receptor 1 family.

RefSeq proteins (1): NP_543007* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000276	GPCR_Rhodpsn	Family
IPR017452	GPCR_Rhodpsn_7TM	Domain
IPR042804	GPR82	Family

Pfam: PF00001

UniProt features (16 total): topological domain 7, transmembrane region 6, glycosylation site 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96P67-F1	84.08	0.42

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (2): 3, 4

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 73 (showing top): GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_RESPONSE_TO_FOOD, GOBP_GLYCEROLIPID_METABOLIC_PROCESS, GOBP_RESPONSE_TO_INSULIN, GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_RESPONSE_TO_HORMONE, GOBP_LIPID_METABOLIC_PROCESS, GOBP_NEUTRAL_LIPID_METABOLIC_PROCESS, MAF_Q6, GOBP_MULTICELLULAR_ORGANISMAL_LEVEL_HOMEOSTASIS, GOBP_ENERGY_HOMEOSTASIS, GOBP_CONNECTIVE_TISSUE_DEVELOPMENT, TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_UP, PITX2_Q2, GOBP_ADIPOSE_TISSUE_DEVELOPMENT

GO Biological Process (8): triglyceride metabolic process (GO:0006641), response to glucose (GO:0009749), response to food (GO:0032094), response to insulin (GO:0032868), adipose tissue development (GO:0060612), energy homeostasis (GO:0097009), signal transduction (GO:0007165), G protein-coupled receptor signaling pathway (GO:0007186)

GO Molecular Function (1): G protein-coupled receptor activity (GO:0004930)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
acylglycerol metabolic process	1
response to hexose	1
response to nutrient levels	1
response to chemical	1
response to peptide hormone	1
animal organ development	1
connective tissue development	1
multicellular organismal-level homeostasis	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
G protein-coupled receptor activity	1
signal transduction	1
transmembrane signaling receptor activity	1
G protein-coupled receptor signaling pathway	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

402 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GPR82	EFHC2	Q5JST6	888
GPR82	GPR162	Q16538	560
GPR82	GPR142	Q7Z601	528
GPR82	GPR19	Q15760	515
GPR82	GPR26	Q8NDV2	497
GPR82	UBA1	P22314	497
GPR82	GPR150	Q8NGU9	491
GPR82	GPR62	Q9BZJ7	491
GPR82	GPR152	Q8TDT2	490
GPR82	GPR52	Q9Y2T5	490
GPR82	CASK	O14936	472
GPR82	GPR27	Q9NS67	452
GPR82	JPT2	Q9H910	447
GPR82	GPR146	Q96CH1	445
GPR82	GPR85	P60893	442

IntAct

0 interactions, top by confidence:

ESM2 similar proteins: A1A5S3, A5PLE7, B0UXR0, B5X337, F5HDK1, F5HF62, F8VQN3, O00421, O18982, O97663, P09703, P32249, P35351, P35374, P46002, P49685, P50052, P51676, P56412, P69332, P69333, Q01035, Q0II78, Q0VDU3, Q14330, Q1RMI1, Q28929, Q3T0E9, Q3U507, Q4R613, Q6IYF9, Q75ZH0, Q83207, Q89609, Q8BZR0, Q8IYL9, Q8K1Z6, Q95N03, Q96P67, Q98146

Diamond homologs: O00270, O02836, P49019, P49146, P79113, P97295, Q5IS62, Q80Z39, Q8BZR0, Q96P67, Q99678, Q9DDN6, Q9GK74, Q9J5I0, Q9Z2D5, B9VR26, E7F7V7, F8VQN3, O02464, O09047, O55197, O62709, O77408, O77590, O88634, O88680, P11614, P21451, P24530, P28088, P30555, P30994, P35463, P48302, P51582, P51679, P56497, Q09QM4, Q16581, Q17232

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

4 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	2
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
1047883	GRCh37/hg19 Xp11.4-11.3(chrX:39645568-44199000)	Pathogenic
832451	NC_000023.11:g.(?41520400)(41923008_?)del	Pathogenic

SpliceAI

156 predictions. Top by Δscore:

Variant	Effect	Δscore
X:41724288:AGGTA:A	donor_loss	0.9900
X:41724289:GGT:G	donor_loss	0.9900
X:41724290:GT:G	donor_loss	0.9900
X:41724291:T:A	donor_loss	0.9900
X:41726759:ATTTT:A	acceptor_loss	0.9900
X:41726767:TTTCA:T	acceptor_loss	0.9900
X:41726768:TTCA:T	acceptor_loss	0.9900
X:41726769:TCA:T	acceptor_loss	0.9900
X:41726770:CAGAC:C	acceptor_loss	0.9900
X:41726771:A:AG	acceptor_gain	0.9900
X:41726772:G:GG	acceptor_gain	0.9900
X:41726772:GAC:G	acceptor_gain	0.9900
X:41726772:GACAA:G	acceptor_gain	0.9900
X:41726764:GTTTT:G	acceptor_loss	0.9800
X:41726765:TTTTT:T	acceptor_loss	0.9800
X:41726766:TTTTC:T	acceptor_loss	0.9800
X:41726772:GA:G	acceptor_gain	0.9800
X:41726772:GACA:G	acceptor_gain	0.9800
X:41726819:A:AG	acceptor_gain	0.9800
X:41726991:A:AG	acceptor_gain	0.9800
X:41726992:G:GG	acceptor_gain	0.9800
X:41726763:T:A	acceptor_loss	0.9700
X:41724290:G:GG	donor_gain	0.9600
X:41726822:C:A	acceptor_gain	0.9600
X:41726819:AACC:A	acceptor_gain	0.9500
X:41726839:AAAAG:A	donor_loss	0.9400
X:41726840:AAAGG:A	donor_loss	0.9400
X:41726841:AAGGT:A	donor_loss	0.9400
X:41726842:AGGTA:A	donor_loss	0.9400
X:41726843:GGT:G	donor_loss	0.9400

AlphaMissense

2202 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:41727330:A:C	S102R	0.996
X:41727332:T:A	S102R	0.996
X:41727332:T:G	S102R	0.996
X:41727342:A:C	S106R	0.996
X:41727344:T:A	S106R	0.996
X:41727344:T:G	S106R	0.996
X:41727933:A:C	S303R	0.996
X:41727935:C:A	S303R	0.996
X:41727935:C:G	S303R	0.996
X:41727376:G:C	R117P	0.994
X:41727930:A:C	S302R	0.994
X:41727932:T:A	S302R	0.994
X:41727932:T:G	S302R	0.994
X:41727196:T:C	L57P	0.993
X:41727288:T:A	C88S	0.993
X:41727289:G:C	C88S	0.993
X:41727912:T:C	C296R	0.993
X:41727940:A:G	D305G	0.993
X:41727269:G:C	W81C	0.992
X:41727269:G:T	W81C	0.992
X:41727372:A:C	S116R	0.992
X:41727374:C:A	S116R	0.992
X:41727374:C:G	S116R	0.992
X:41727817:C:G	P264R	0.992
X:41727187:T:C	L54P	0.991
X:41727209:C:A	N61K	0.991
X:41727209:C:G	N61K	0.991
X:41727494:C:G	C156W	0.991
X:41727504:T:A	W160R	0.991
X:41727504:T:C	W160R	0.991

dbSNP variants (sampled 300 via entrez): RS1000014335 (X:41726803 T>C), RS1000403661 (X:41723836 C>A), RS1002100029 (X:41729553 A>G), RS1002155560 (X:41729234 C>A,G,T), RS1004116239 (X:41725006 C>A), RS1004146963 (X:41730269 G>A), RS1005636685 (X:41729273 T>G), RS1005752869 (X:41730103 G>A), RS1006982932 (X:41729097 T>G), RS1008195449 (X:41726086 A>T), RS1008247527 (X:41725782 A>C,G), RS1008531858 (X:41723669 C>T), RS1010767072 (X:41728063 T>A,C), RS1010805765 (X:41724494 G>T), RS1010810945 (X:41728673 C>T)

Disease associations

OMIM: gene MIM:300748 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): cardiomyopathy (MONDO:0004994)

Orphanet (1): Rare cardiomyopathy (Orphanet:167848)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D009202	Cardiomyopathies	C14.280.238

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4523907 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — Class A Orphans with no pharmacology

CTD chemical–gene interactions

7 total (human), top 7 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
GSK-J4	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	decreases expression, affects response to substance, increases expression, affects cotreatment	1
theaflavin-3,3’-digallate	affects expression	1
Lipopolysaccharides	decreases expression, affects response to substance, increases expression, affects cotreatment	1
Tretinoin	increases expression	1
Aflatoxin B1	decreases methylation	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4883469	Binding	PRESTO-Tango GPCRome screening (GPR82)	Data for DCP probe UCSF924

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00348530	PHASE4	UNKNOWN	Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy
NCT00371891	PHASE4	COMPLETED	Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS)
NCT00401856	PHASE4	COMPLETED	CMR to Assess Fibrosis in Cardiomyopathy Using Eplerenone
NCT00559338	PHASE4	COMPLETED	Impact of Nesiritide Infusion for Decompensated Heart Failure in the Emergency Department
NCT00606775	PHASE4	UNKNOWN	The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy
NCT00658203	PHASE4	COMPLETED	Clinical Evaluation on Advanced Resynchronization
NCT00701220	PHASE4	COMPLETED	Statin Therapy for Ischemic and Nonischemic Cardiomyopathy
NCT00800761	PHASE4	COMPLETED	Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major
NCT00806390	PHASE4	TERMINATED	Prevention of Anthracycline or Trastuzumab Induced Cardiomyopathy by Metoprolol
NCT01006473	PHASE4	COMPLETED	Exercise Training in Chagas Cardiomyopathy
NCT01261065	PHASE4	COMPLETED	Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure
NCT01345188	PHASE4	COMPLETED	Ranolazine in Ischemic Cardiomyopathy
NCT01868841	PHASE4	COMPLETED	123-I mIBG (AdreView) Heart-to-Mediastinal (H/M) Ratio and SPECT Imaging on a Small Field of View-High Efficiency Cardiac SPECT System
NCT02640846	PHASE4	UNKNOWN	Effects of Levosimendan, Milrinone and Norepinephrine on Left and Right Ventricular Function in Septic Shock
NCT03228823	PHASE4	UNKNOWN	Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy(PAPS)
NCT04323852	PHASE4	COMPLETED	Can Vitamin D Reduce Heart Muscle Damage After Bypass Surgery?
NCT05034432	PHASE4	RECRUITING	The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients
NCT05718128	PHASE4	RECRUITING	Clinical Study of Endocardial Myocardial Biopsy
NCT06964464	PHASE4	RECRUITING	Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator
NCT00170183	PHASE3	COMPLETED	Brain Natriuretic Peptide (BNP) to Preserve Renal Function in Hospitalized Patients With Heart Failure
NCT00270387	PHASE3	COMPLETED	A Study of Short-Term Outcomes and Economic Impact For Patients With Worsening Congestive Heart Failure When Natrecor (Nesiritide) is Added to Standard-Care Therapy, Compared to Administration of Placebo With Standard-Care Therapy
NCT00321295	PHASE3	COMPLETED	Biventricular Pacing In Patients With Left Ventricular Dysfunction After Cardiovascular Surgery
NCT00483197	PHASE3	UNKNOWN	VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Pivotal Trial
NCT00490321	PHASE3	UNKNOWN	VentrAssistTM LVAD for the Treatment of Advanced Heart Failure - Destination Therapy
NCT00626028	PHASE3	COMPLETED	Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing
NCT01013714	PHASE3	UNKNOWN	Cardiac Sympathetic Denervation for Prevention of Ventricular Tachyarrhythmias
NCT01217827	PHASE3	COMPLETED	Implantable Cardioverter-Defibrillator Use in the VA System
NCT01648634	PHASE3	COMPLETED	Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy
NCT02924285	PHASE3	COMPLETED	Catheter Ablation Versus Amiodarone for Therapy of Premature Ventricular Contractions in Patients With Structural Heart Disease
NCT03860935	PHASE3	COMPLETED	Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
NCT04166331	PHASE3	COMPLETED	Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion
NCT05175066	PHASE3	COMPLETED	Bisoprolol Administration to Prevent Anthracycline-induced Cardiotoxicity
NCT05237323	PHASE3	COMPLETED	Micophenolate Mofetil Versus Azathioprine in Myocarditis
NCT06158698	PHASE3	RECRUITING	CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine
NCT06563895	PHASE3	RECRUITING	Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06846086	PHASE3	RECRUITING	Cardioprotective Effects of Melatonin in Patients With Cardiomyopathy
NCT07116473	PHASE3	NOT_YET_RECRUITING	To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
NCT00185250	PHASE2	COMPLETED	Betaferon/ Betaseron (Interferon Beta-1b) in Patients With Chronic Viral Cardiomyopathy
NCT00490347	PHASE2	COMPLETED	VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Feasibility Trial
NCT00694161	PHASE2	COMPLETED	The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy